Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Panel
Biykem Bozkurt, Gregg C Fonarow, Lee R Goldberg, Maya Guglin, Richard A Josephson, Daniel E Forman, Grace Lin, JoAnn Lindenfeld, Chris O'Connor, Gurusher Panjrath, Ileana L Piña, Tina Shah, Shashank S Sinha, Eugene Wolfel, ACC’s Heart Failure and Transplant Section and Leadership Council, Biykem Bozkurt, Gregg C Fonarow, Lee R Goldberg, Maya Guglin, Richard A Josephson, Daniel E Forman, Grace Lin, JoAnn Lindenfeld, Chris O'Connor, Gurusher Panjrath, Ileana L Piña, Tina Shah, Shashank S Sinha, Eugene Wolfel, ACC’s Heart Failure and Transplant Section and Leadership Council
Abstract
Cardiac rehabilitation is defined as a multidisciplinary program that includes exercise training, cardiac risk factor modification, psychosocial assessment, and outcomes assessment. Exercise training and other components of cardiac rehabilitation (CR) are safe and beneficial and result in significant improvements in quality of life, functional capacity, exercise performance, and heart failure (HF)-related hospitalizations in patients with HF. Despite outcome benefits, cost-effectiveness, and strong practice guideline recommendations, CR remains underused. Clinicians, health care leaders, and payers should prioritize incorporating CR as part of the standard of care for patients with HF.
Keywords: activity; cardiac rehabilitation; exercise; exercise training; functional status; heart failure.
Conflict of interest statement
Funding Support and Author Disclosures Dr. Bozkurt has received consulting fees from Bristol Myers Squibb, scPharmaceuticals, Baxter Healthcare Corporation, Sanofi, and Relypsa; serves on the Clinical Event Committee for the GUIDE-HF trial, sponsored by Abbott Vascular; and serves on the Data and Safety Monitoring Committee of the ANTHEM trial, sponsored by LivaNova. Dr. O’Connor has received grant or research support from Roche Diagnostics, Merck, and Bayer; and has received consulting fees from Merck, Bayer, Bristol Myers Squibb, Windtree Therapeutics, and Arena. Dr. Forman has received funds from the National Institute on Aging and the National Institutes of Health Common Fund through grants R01AG060499, R01AG058883, P30AG024827, and UO1AR071130. Dr. Fonarow has received research funding from the National Institutes of Health; and has received consulting fees from Abbott, Amgen, AstraZeneca, Bayer, CHF Solutions, Edwards Lifesciences, Janssen, Medtronic, Merck, and Novartis. Dr. Panjrath has received speaker fees from Pfizer. Dr. Piña has received advisory board fees from Relypsa. Dr. Lindenfeld has received consulting fees from Abbott, AstraZeneca, CVRx, Boehringer Ingelheim, Edwards Lifesciences, Impulse Dynamics, and VWave; and has received grant support from AstraZeneca, Volumetric, and Sensible Medical. Dr. Goldberg has received consulting fees from Respicardia and Abbott; has served on the steering committee of the Remede Pivotal Trial, sponsored by Respicardia; and is the current principal investigator of the REST trial, sponsored by Respicardia. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Published by Elsevier Inc.
Source: PubMed